Discover how Medicare coverage for NeoGenomics' RaDaR ST assay enhances cancer treatment monitoring and patient management options.

Personalis updates valuation with a raised fair value to $11 per share driven by Medicare reimbursement for its NeXT Personal test and strong Q3 revenue performance. Analysts see durable revenue growth and clinical validation as key drivers.